Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SymBio On Radar Of VC Firms And Small Biotechs For Tapping Japan's Specialty Market; Signs With Onconova

This article was originally published in PharmAsia News

Executive Summary

TOKYO - SymBio Pharmaceuticals Ltd. is catching the eyes of small biotechs looking for partners in the Japanese market since gaining approval for its first drug last year. Onconova Therapeutics Inc. tied up with SymBio in Japan and South Korea for the first commercial license of its lead compound, the multikinase inhibitor rigosertib
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC078564

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel